Partial
Partially Aligned
Patient Risk:
Low
Summary
The AI response largely does not align with the provided FDA label. Most claims are not supported by label text, one claim is only partially supported, and several relevant safety/indication aspects are omitted.
Category Scores
Accurate Statements
Unsupported Statements
The brand-name Suboxone film is manufactured by Indivior [4].
Not found in label sections 11 or 3.
The first generic versions of buprenorphine and naloxone sublingual film became available in the United States in 2018 [3].
Not found in label sections 11 or 3.
Numerous pharmaceutical companies produce generic buprenorphine and naloxone sublingual films.
Not found in label sections 11 or 3.
Generic buprenorphine and naloxone sublingual films are chemically equivalent to Suboxone.
Label does not state chemical equivalence; may refer to bioequivalence; not explicitly stated.
Yes, other formulations of buprenorphine, such as tablets or injections, are available for opioid use disorder treatment.
Label 2.9 discusses switching between products; does not explicitly claim general availability of other formulations.
Additionally, methadone is another medication-assisted treatment option [5].
Label does not mention methadone in Suboxone labeling.
The choice of medication and formulation often depends on individual patient needs, physician recommendation, and insurance coverage.
Label discusses indications, dosing, and safety but not payer/physician decision factors.
The primary patents for Suboxone film expired years ago, allowing for the introduction of generic versions.
Patent status is not in label.
Contradictions
Important Omissions
Indication (approved use) and patient population details.
Importance:
High
Contraindications and boxed warnings.
Importance:
High
Warnings and precautions and drug interactions.
Importance:
High
Use in specific populations (pregnancy, nursing mothers, hepatic impairment, elderly).
Importance:
High
Adverse reactions and monitoring recommendations.
Importance:
High
Administration instructions and storage/handling details.
Importance:
High
Safety Assessment
Potential Patient Risk:
Low
No safety-critical statements are supported; multiple substantial omissions reduce overall safety alignment.
Regulatory Assessment
| On Label |
Yes |
| Off-label Discussion |
No |
| Promotes Unapproved Use |
No |
| Hallucination Risk |
Low |
Recommendation
Partially Aligned
Primary Issue
Claims largely not supported by label; one claim partially supported.
Suggested Improvement
Restrict claims to information present in label sections (e.g., 2.9, 11, 3); avoid extrapolation; cite exact label statements; include missing label sections (indication, contraindications, boxed warnings, interactions, monitoring, administration, storage).